(MENAFN - Newsfile Corp) Xfuels Inc. Shareholder Update
Calgary, Alberta (Newsfile Corp. - February 17, 2021) - Xfuels Inc. (OTC PINK: XFLS) is pleased to report the following Share holder update. 2020 In Retrospect
Well, I would guess that it is safe to say 2020 did not go as planed however the year is behind us and although slower than anticipated we continued to grow. We anticipate 2021 being a defining year for the company with steady growth and working to meet our objectives. Acquisitions
On June 8th, 2020 Xfuels announced it has purchased the outstanding shares of Cycle Energy Industries Ltd. for the sum of 5,000,000 USD. As of February 16th, this deal is still pending, COVID-19 delays have hindered our ability to close however we have a firm deal pending 2 conditions on pricing and the company being current. Both are being addressed and we expect this to be fulfilled as quick as possible.
Kore Mining Announces Appointment of Vice President, Investor Relations
News provided by
Share this article
KORE or the
Company ) is pleased to announce the appointment of Liz Monger as Vice President, Investor Relations, effective February 17 2021.
Ms. Monger has 25 years of investor relations, communications and compliance experience and was most recently the Manager of Investor Relations and Corporate Secretary at Midas Gold Corp. from June 2011 to January 2021. During her time at Midas Gold, Ms. Monger led investor relations for the Company and was a key part of the project communications team that built an alliance of Idaho mining companies. Prior to joining Midas Gold, Ms. Monger spent six years with Rainy River Resources Ltd., departing as Director of Investor Relations, and before that was responsible for Corporate Communications, Compliance and Land Management at Rubicon Minerals Corporation.
ATC approves two-day physical remand of PTI s Haleem Adil Sheikh
Published On
Four cases under terrorism sections have been lodged against Haleem Adil Sheikh.
KARACHI (Dunya News) – An anti-terrorism court (ATC) in Karachi has on Wednesday approved two-day physical remand of Leader of the Opposition in the Sindh Assembly and Pakistan Tehreek-e-Insaf (PTI) leader Haleem Adil Sheikh and others.
Deputy Attorney-General Wahab Baloch appeared before the court as Haleem Adil Sheikh’s counsel and argued that the case is based on dishonesty. The court remarked that it has initially approved two-day remand, and will further analyze the situation after investigation.
Bionomics Limited (ASX: BNO,OTCQB: BNOEF, Germany: AU000000BNO5) (
Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (
EmpathBio), a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences (
atai). Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics BNC210 and EmpathBio s 3,4-Methylenedioxymethamphetamine (MDMA) derivative EMP-01. The parties will explore whether the different mechanisms of action of EMP-01 and BNC210 may offer the potential for developing an improved treatment regimen for the treatment of Post-Traumatic Stress Disorder (PTSD).
BNC210 is Bionomics lead drug candidate, which has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of PTSD and other trauma-related and stress-related disorders. A new solid dose formulation of BNC210 ha
Almirall and MC2 Therapeutics enter a license, collaboration and commercialization agreement for European rights to Wynzora® Cream for treatment of plaque psoriasis
USA - English In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply MC2 Therapeutics and Almirall partner to make Wynzora® Cream a leading topical product for Plaque Psoriasis in Europe In a large European based Phase 3 clinical trial (n=490), Wynzora® Cream has demonstrated substantial efficacy with a PGA treatment success of 51% and beneficial treatment convenience[1] Marketing Authorization Application (MAA) in Europe of Wynzora® Cream has been filed and approval is expected this year